FDA regulatory pathway

FDA Fast-Track designation remains one of the most strategically significant regulatory tools available to biotechnology sponsors in the United States. Designed to expedite development and review of drugs that address serious conditions and unmet medical needs, the program influences clinical planning, investor perception, and commercialisation timing. In 2026, Fast-Track designation is not merely a procedural … Read more